Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach™ is a natural product that will help address global concerns around the overuse of antibiotics in animals and their feed that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Latest news All news
Anatara’s Chairman Mel Bridges conducted an interview recently with the Australian Associated Press which published an article that was widely reproduced across many media outlets.
The article highlighted that Anatara was raising $7 million in an initial public offering and would list on the Australian Securities Exchange.
It noted that Anatara’s lead product, DetachTM is a non-antibiotic medicine made from an extract from pineapple roots to treat and prevent diarrhoea in food production animals and planned to be first used in pigs.
US President Barack Obama has issued an Executive Order that aims to combat the rise of antibiotic resistant bacteria that represent a serious threat to public health and the economy.
It says the US Federal Government will work domestically and internationally to “detect, prevent, and control illness and death related to antibiotic-resistant infections by implementing measures that reduce the emergence and spread of antibiotic-resistant bacteria and help ensure the continued availability of effective therapeutics for the treatment of bacterial infections”.
Measures to tackle antimicrobial resistance include eliminating “the use of medically important classes of antibiotics for growth promotion purposes in food-producing animals”.
The Executive Order can be found here.
A report to the President on combating antibiotic resistance by the President’s Council of Advisors on Science and Technology can be found here.
The Anatara team met senior business journalist Tim Boreham from The Australian newspaper recently to brief him on Anatara and our plans. He notes we’re raising $7 million from investors and that we’re intending to conduct new trials to get Detach re-registered in Australia. He suggests people read our prospectus when it’s lodged.
Read more here.